The Safe and Affordable Drugs from Canada Act of 2025 would amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drugs from approved Canadian pharmacies for personal use, subject to safeguards. Importation would require a valid U.S. physician prescription, a maximum 90-day supply, and alignment in active ingredients, dosage form, and strength with FDA-approved equivalents.
The Secretary must promulgate implementing regulations within 180 days of enactment and publish a list of approved Canadian pharmacies that meet defined standards.
At a Glance
What It Does
The bill adds a new Section 810 to the FD&C Act to permit individuals to safely import prescription drugs from Canada, provided the drugs come from approved Canadian pharmacies and meet specified conditions (personal use, 90-day supply, U.S. physician prescription, and equivalence to FDA-approved products). It also excludes certain drug classes.
Who It Affects
Individuals in the United States seeking affordable prescription medicines, licensed Canadian pharmacies, U.S. physicians who certify prescriptions, and FDA regulators responsible for implementation.
Why It Matters
If implemented, it creates a controlled cross-border access path that could lower patient costs while maintaining safety standards through certification of Canadian pharmacies and prescribed-use limits.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill would create a new framework under which people in the United States could legally import prescription drugs from Canada for personal use. The drugs must come from pharmacies in Canada that are approved by the FDA and meet certain standards, including proper licensing, quality assurance, and compliance programs.
The importation is limited to a 90-day supply and requires a prescription from a U.S.-licensed physician, with the drug having the same active ingredients, dosage form, and strength as its FDA-approved counterpart. Importation would be regulated through new FDA regulations to be issued within 180 days of enactment, and the FDA would publish a list of approved Canadian pharmacies on its website.
The bill also outlines a set of drugs that are not eligible for import, including controlled substances, biologics, infused, intravenously injected, and several biotechnology-derived products, as well as drugs requiring refrigeration or other special handling, among other exclusions. The overall aim is to expand access to affordable medicines while maintaining safety and oversight through a standardized approval and monitoring process.
The mechanism relies on a trusted network of Canadian pharmacies and federal verification to ensure that imported drugs are safe and equivalent to their U.S.-approved versions. Implementation would require coordination between the FDA, state pharmacy regulators, and participating Canadian pharmacies to monitor quality, resolve grievances, and prevent resale to U.S. consumers.
The approach signals a deliberate balance between patient access and regulatory control, with clear guardrails to mitigate safety risks.
The Five Things You Need to Know
The bill creates Section 810 to permit personal importation of prescription drugs from approved Canadian pharmacies.
Importable drugs must come from Canadian pharmacies licensed to dispense in Canada and meet FDA-equivalence standards.
A 90-day supply limit applies, and U.S. prescriptions are required for imported drugs.
A list of approved Canadian pharmacies must be published by the FDA, and these pharmacies must meet stringent qualification criteria.
The act excludes several drug categories (controlled substances, biologics, infused or parenteral drugs, certain biotech products, and drugs needing refrigeration).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Importation framework and drug eligibility
This subsection establishes the mechanism for individual importation. Not later than 180 days after enactment, the Secretary must issue regulations that permit individuals to import prescription drugs from approved Canadian pharmacies for personal use. The imported drug must be dispensed in Canada by a licensed pharmacist, be intended for personal use in the United States (not for resale), and require a valid U.S. physician prescription. The drug must be the same active ingredient, strength, and dosage form as an FDA-approved product and not be a prohibited category (e.g., controlled substances, biologics, infused, intravenous, inhaled during surgery, or other listed exceptions). All imports are subject to the regulatory framework established by the FDA and related agencies.
Approved Canadian Pharmacy — eligibility
An approved Canadian pharmacy is a licensed operation located in Canada that is certified by the Secretary as meeting criteria designed to ensure safety and reliability. Certification requires the pharmacy to be licensed to dispense prescription drugs in Canada, and to have a purpose beyond participation in the import program. The approval status relies on demonstrated compliance with applicable Canadian pharmacy laws and regulatory standards.
Publication and additional criteria
The Secretary must publish on the FDA website a list of approved Canadian pharmacies, including their website addresses. To be approved, a pharmacy must meet multiple criteria: at least five years in operation with a non-import-only purpose; adherence to provincial pharmacy rules; established processes to verify premises, licensing, and data reporting; ongoing quality assurance programs with testing to ensure product safety; usage of FDA-approved laboratories for product testing; grievance resolution processes; a prohibition on reselling products from online Canadian pharmacies to U.S. customers; and any other criteria the Secretary deems necessary for safety and reliability.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- US patients and families facing high prescription drug costs who can access more affordable medications through a Canada-based supply channel with regulatory oversight.
- Uninsured or underinsured individuals who struggle with affordability and may gain a legitimate option for obtaining necessary therapies.
- Licensed U.S. physicians who can issue prescriptions with confidence in cross-border supply when appropriate.
- Approved Canadian pharmacies that meet the criteria and gain access to a new customer base while maintaining compliance.
- Health plans and employers that face rising drug costs and could benefit from broader price competition.
Who Bears the Cost
- FDA will shoulder initial and ongoing regulatory duties, including issuing the rules, maintaining the approved-pharmacy list, and monitoring compliance and safety.
- State boards of pharmacy and other U.S. regulators may need to coordinate enforcement and ensure cross-border practices align with state laws.
- Participating Canadian pharmacies must maintain QA programs, testing, complaint processes, and cross-border documentation, incurring ongoing compliance costs.
- Cross-border supply-chain and labeling oversight may require additional administrative resources at multiple points in the process.
- Payers and insurers could experience shifts in drug pricing dynamics and claims processing as competition increases.
Key Issues
The Core Tension
Balancing patient access and drug affordability with the safety, reliability, and regulatory burden of cross-border drug importation.
The bill creates a pathway for international drug access, but it also raises tensions between access and safety. By tying import eligibility to approved Canadian pharmacies and a defined set of drug categories, it attempts to mitigate safety risks while expanding consumer choice.
However, implementation will require substantial regulatory coordination across federal agencies and, potentially, state regulators, to ensure that imported drugs are clinically equivalent, properly labeled, and not resold or diverted. The design relies on robust quality assurance, ongoing monitoring, and a credible, auditable chain of custody for products sourced in Canada.
Unanswered questions include how disputes and quality failures will be handled at scale, and how enforcement will function if counterfeit or substandard products enter the market under this framework.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.